General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Healthcare portfolio

As a science-based and patient-oriented healthcare, we strive to be a global leader in growing areas of healthcare. Novartis focuses its business on three leading divisions with strong innovation power and global scale: pharmaceuticals, eye care and generics. These three leading divisions are supported by our research organization, the Novartis Institutes for BioMedical Research (NIBR), and a centralized services group, Novartis Business Services, to facilitate collaboration across our divisions, and drive efficiency and productivity gains. We aim to develop innovative products in growing areas of healthcare. At the same time, we are expanding our presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high-quality medicines and healthcare.


Our global Pharmaceuticals portfolio includes more than 50 key marketed products, many of which are innovative leaders in their therapeutic areas.

Alcon (Eye Care)

Alcon provides innovative products that enhance quality of life by helping people worldwide see better. Its three businesses – Surgical, Ophthalmic Pharmaceuticals and Vision Care – offer the world's widest spectrum of eye care products.

Sandoz (Generics)

Sandoz is a global leader in the rapidly growing generics industry, offering more than 1,000 different types of high-quality, affordable medicines across a broad range of therapeutic areas. It is committed to increasing global access to affordable medicine.